These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37633033)

  • 1. Real world study of ocrelizumab in multiple sclerosis: Kuwait experience.
    Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
    Mult Scler Relat Disord; 2023 Nov; 79():104941. PubMed ID: 37633033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
    Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
    Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
    Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.
    Erdogan T; Cansu C; Kocer B; Akkaya S; Kokmen H
    Acta Neurol Belg; 2024 Aug; 124(4):1385-1391. PubMed ID: 38769274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
    Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
    Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocrelizumab for multiple sclerosis.
    Lin M; Zhang J; Zhang Y; Luo J; Shi S
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
    Houtchens M; Howard D
    Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.
    Cellerino M; Boffa G; Lapucci C; Tazza F; Sbragia E; Mancuso E; Bruschi N; Minguzzi S; Ivaldi F; Poirè I; Laroni A; Mancardi G; Capello E; Uccelli A; Novi G; Inglese M
    Neurotherapeutics; 2021 Oct; 18(4):2579-2588. PubMed ID: 34553320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study.
    Rodriguez de Antonio LA; Cuberta-Gonzalez I; Garcia-Castañon I; Oreja-Guevara C
    Mult Scler Relat Disord; 2023 Jan; 69():104441. PubMed ID: 36493559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocrelizumab in pediatric multiple sclerosis.
    Bibinoğlu Amirov C; Saltık S; Yalçınkaya C; Tütüncü M; Saip S; Siva A; Uygunoğlu U
    Eur J Paediatr Neurol; 2023 Mar; 43():1-5. PubMed ID: 36724688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocrelizumab: A Review in Multiple Sclerosis.
    Lamb YN
    Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R; Al-Hashel J; Ahmed SF
    Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain.
    Sempere AP; Berenguer-Ruiz L; Borrego-Soriano I; Burgos-San Jose A; Concepcion-Aramendia L; Volar L; Aragones M; Palazón-Bru A
    Front Neurol; 2020; 11():592304. PubMed ID: 33519676
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
    Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
    Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab initiation in patients with MS: A multicenter observational study.
    Ellwardt E; Rolfes L; Klein J; Pape K; Ruck T; Wiendl H; Schroeter M; Zipp F; Meuth SG; Warnke C; Bittner S
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32273482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
    Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
    Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
    BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
    Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
    Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.